- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04505371
Improving the Reach & Effectiveness of Smoking Cessation Services Targeted to Veterans Living With HIV (WISH)
Improving the Reach and Effectiveness of Smoking Cessation Services Targeted to Veterans Living With HIV
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Tobacco use remains the leading preventable cause of death and illness in our society, and smoking rates are disproportionately high among people living with HIV. NCI, nicotine dependence researchers, and HIV clinicians have all called for research to evaluate targeted and tailored smoking cessation programs for smokers living with HIV (SLWH). Research suggests SLWH are largely unaware of the HIV-specific deleterious effects of smoking and often lack motivation and confidence in their ability to quit. For these reasons, we developed the Wellness Intervention for Smokers with HIV (WISH).
Similar to standard care cessation services available to Veterans, WISH is delivered remotely by mobile phone (voice and text message). The program is designed for all SLWH, regardless of their initial motivation to quit. WISH follows evidence-based, best practice guidelines for nicotine dependence treatment, but is innovative in its use of a more comprehensive wellness approach. That is, the intervention addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all SLWH, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals.
Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study, allowing use of these standard services to be compared across study groups.
In this two-group randomized trial, we will compare the effectiveness of WISH to standard care services offered through the National VA Quitline and the SmokefreeVET texting program (tobacco cessation services available to all Veterans). Participants in both study groups can receive phone/ text counseling and have access to pharmacotherapy through VA. Cessation services in both study groups will be provided and overseen by the non-VA sites that developed each program.
Smoking-related outcomes will include 7-day point prevalence smoking abstinence and presence of any 24-hour intentional quit attempts, prolonged abstinence, and change in cigarettes per day. We will measure change in smoking-related knowledge, motivation and behavioral skills, as well as intervention reach and implementation. We will also describe comorbidities and explore intervention impact on markers of immune status and mortality risk using clinical data resources available through the Veterans Aging Cohort Study (VACS).
If effective, WISH could meaningfully increase the reach of cessation services and reduce smoking among HIV+ Veterans nationwide. To support this goal, dissemination efforts are planned in Year 5 to share the WISH program with the National VA Quitline. Because VA is the largest U.S. provider of HIV care, this research has the potential for significant public health impact.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: John Kundzins, BS
- Phone Number: (206) 268-5278
- Email: John.Kundzins@VA.gov
Study Contact Backup
- Name: Kristina Crothers, MD
- Phone Number: (206) 277-3013
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98108
- Recruiting
- VA Puget Sound Health Care System Seattle Division
-
Contact:
- John Kundzins, BS
- Phone Number: 206-768-5278
- Email: John.Kundzins@va.gov
-
Principal Investigator:
- Kristina A Crothers, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- In care in the VA
- HIV+ serostatus
- Currently smoking 5+ cigarettes daily
- Access to cell phone with text messaging capabilities
- English speaking
Exclusion Criteria:
- Psychosis, dementia or significant cognitive impairment documented in the EHR
- Documented or observed hearing or comprehension difficulties that would preclude participation in study telephone calls
- Currently receiving cessation counseling or using an FDA approved treatment to quit smoking
- Institutionalized/imprisoned
- Pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control - Standard Care
The control intervention is referral to standard evidence-based cessation services available nationally to Veterans, including the National VA Quitline and SmokefreeVET texting program.
|
|
Experimental: Intervention - Wellness Intervention for Smokers with HIV
The experimental WISH intervention is an HIV-specific comprehensive wellness program designed to offer integrated phone and text counseling regardless of readiness to quit.
|
WISH is delivered remotely by mobile phone (voice and text message). WISH addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals. Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
7-day point-prevalence abstinence (PPA)
Time Frame: 6 months post-randomization
|
Smoking abstinence at 6-month follow-up by self-report and biochemically confirmed via saliva cotinine for a small selected group of individuals.
Cotinine levels < 10 ng/ml and a self-report of 7 day PPA will be required to be coded a nonsmoker.
|
6 months post-randomization
|
Any 24-hour intentional quit attempt
Time Frame: 3 and 6 months postrandomization
|
The primary outcome will be presence of an intentional quit attempt [yes/no] reported between randomization and 6 month follow-up.
Quit attempts will be assessed at each follow-up.
|
3 and 6 months postrandomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Floating prolonged abstinence
Time Frame: 3 and 6 months post-randomization
|
A proxy for sustained abstinence appropriate for evaluating a motivational intervention, in which the start point floats based on one's actual quit date rather than a pre-determined quit date
|
3 and 6 months post-randomization
|
7-day self-report point-prevalence abstinence (PPA)
Time Frame: 3 and 6 months post-randomization
|
Self-report of abstinence from smoking, even a puff
|
3 and 6 months post-randomization
|
30-day self-report point-prevalence abstinence (PPA)
Time Frame: 3, 6, 12 months post-randomization
|
Self-report of abstinence from smoking, even a puff
|
3, 6, 12 months post-randomization
|
Cigarettes smoked per day
Time Frame: 3 and 6 months post-randomization
|
Self-report; even a puff counts as smoking
|
3 and 6 months post-randomization
|
HIV-specific smoking knowledge
Time Frame: 3 and 6 months post-randomization
|
Items validated in a survey of Smokers Living with HIV conducted by the study team during a study titled "Smoking cessation-related information, motivation, and behavioral skills specific to HIV-infected smokers" (likert scale)
|
3 and 6 months post-randomization
|
Motivation to quit smoking
Time Frame: 3 and 6 months post-randomization
|
1-10 likert scale
|
3 and 6 months post-randomization
|
Smoking cessation related to self-efficacy
Time Frame: 3 and 6 months post-randomization
|
1-10 likert scale on domains (each) of quitting smoking, reducing smoking, managing cravings, and stimulus control
|
3 and 6 months post-randomization
|
Nicotine withdrawal symptom management (behavioral skills)
Time Frame: 3 and 6 months post-randomization
|
Self-report Minnesota Smoking Withdrawal Scale, Revised
|
3 and 6 months post-randomization
|
Cessation medication use and adherence (behavioral skills)
Time Frame: 3 and 6 months post-randomization
|
Self-report and health records (pharmacy) monitoring
|
3 and 6 months post-randomization
|
Absolute CD4 count
Time Frame: 6 and 12 months post-randomization
|
Lab value of CD4 ascertained via EHR
|
6 and 12 months post-randomization
|
VACS index 2.0
Time Frame: 6 and 12 months post-randomization
|
Composite score based of various lab values ascertained via EHR
|
6 and 12 months post-randomization
|
Intentional quit attempt frequency and duration
Time Frame: 3 and 6 months post-randomization
|
Behavioral Risk Factor Surveillance System (BRFSS)
|
3 and 6 months post-randomization
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kristina Crothers, MD, VA Puget Sound Health Care System
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
Other Study ID Numbers
- 1R01CA243907-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Wellness Intervention for Smokers with HIV
-
The University of Texas Health Science Center,...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingMultiple SclerosisUnited States
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
The Miriam HospitalNational Heart, Lung, and Blood Institute (NHLBI)WithdrawnTobacco Use | Acute Coronary SyndromeUnited States
-
University of RochesterNational Cancer Institute (NCI); National Institutes of Health (NIH); New York... and other collaboratorsCompletedTobacco Use DisorderUnited States
-
Pacific Institute for Research and EvaluationFogarty International Center of the National Institute of Health; Kenya Medical... and other collaboratorsActive, not recruitingHIV | Pregnancy in Adolescence | Social Stigma | Mother to Child Transmission | Self DisclosureKenya
-
Columbia UniversityCompletedSexually Transmitted InfectionsUnited States
-
Columbia UniversityCompleted
-
Baylor College of MedicineRecruiting
-
University of Alabama at BirminghamCompletedMultiple SclerosisUnited States
-
Centers for Disease Control and PreventionCompleted